FGFR2 and intrahepatic cholangiocarcinoma: Its safety has been studied in a multicenter, phase 2 trial of patients with advanced or metastatic ICC with FGFR2 gene rearrangements who had disease progression after first line therapy (gemcitabine-cisplatin).